Lexicon Pharma (LXRX) Reports In-Line Q4 EPS
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.05 +0.49%
EPS Growth %: -50.0%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -50.0%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.16), in-line with the analyst estimate of ($0.16). Revenue for the quarter came in at $37 thousand versus the consensus estimate of $50 thousand.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- B.Riley Assumes Anika Therapeutics (ANIK) at Buy
- Arrive AI and DXC Technology partner to bring delivery tech to factories
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
